Phase 1 × NIH × Leukemia, Promyelocytic, Acute × Clear all
NCT02390752 2026-03-13

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
54 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 1 Completed
56 enrolled
NCT00301938 2013-09-30

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00098826 2013-01-11

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled